Curio Wellness is a Maryland based, family owned cultivator and manufacturer that decided years ago to compete on formulation instead of THC percentage. In an interview with IgniteIt, cofounder and chief brand officer Wendy Bronfein laid out how that choice shapes everything: the research they fund, the prices they set, and which products survive. Her summary of the retail game is the whole story in one line. Getting on the shelf is the first step. Staying there is the real accomplishment.
That is the sentence every brand team should tape to the wall. Shelf space is rented, never owned, and the rent comes due every reorder cycle.
Why is clinical research so hard in cannabis?
Ask Bronfein about the company’s biggest business challenge and she points to barriers to clinical research. Curio tests every product in some form before commercialization, from a new chew flavor to complex formulations. When Maryland moved to adult use, the company ran its first placebo controlled study, a Crohn’s trial with institutional review board approval. It ended early after a little more than a year, short of its enrollment target, partly because participants had to collect study products at a dispensary instead of the medical office where they did their visits. Regulators say they want innovation and therapeutic connection for the public. The process does not always match the stated goals. Every operator doing real R and D knows this friction. Curio just said it out loud.
How do you sell against the THC number?
Most shoppers still compare THC content and price. Curio’s answer is to give them a reason to pay more: formulate around cannabinoids, terpenes, and intended effects so the customer is buying an outcome, not a number. Some products carry a premium. Others price in line with the market. The differentiation comes from formulations competitors do not offer, which is a moat that survives the price compression eating undifferentiated markets. When everyone sells the same test result, the only lever left is price. Curio refused that game.
What does building for the FDA look like?
Curio’s manufacturing facility has held current good manufacturing practice certification since 2019. That is not a marketing line. It is a capital decision made years before any federal requirement existed, aimed at retailer confidence and licensing partnerships today and FDA style oversight tomorrow. Bronfein’s framing is direct: the world will change one day, federal regulation is likely coming in some form, so build for it now. Most MSOs talk about federal readiness. Very few spent the money in 2019.
What happens when good products get bad branding?
Curio once paired relaxation, balance, and uplift formulations with a computer themed campaign aimed at millennials. The dispensary audience at the time skewed middle aged and older. The campaign missed. The formulations survived, redeployed into other products with different presentation. That is the right lesson and most companies learn the wrong one. The failure was not the product. It was the assumption about who walks into the store. Killing the branding while keeping the formulation is portfolio discipline in action, the same discipline behind the pricing wars reshaping who survives at retail.
How does a product earn its place?
Curio sets adoption and velocity targets at launch, then watches reorders and margin. Miss the targets and the product gets repriced, reformulated, or retired. A product customers like can still fail if they will not pay what it costs to make. Bronfein’s question for every SKU says it all: if it does not earn its place, do we fix it or retire it. As markets crowded, the company got more selective, protecting the products consumers rely on while keeping capacity for new development. Having a curated, stronger portfolio wins. Retailers feel the difference too, which is why Curio invests in budtender education, product sheets, and field teams that keep visiting stores after the sale, the unglamorous work that separates brands that stay on shelves from brands that just land on them.
Earn the shelf every single reorder. That is the whole business.
FAQs
- What is Curio Wellness?
A Maryland based, family owned cannabis cultivator and manufacturer focused on effect targeted formulations, from better sleep to relaxation. - What is its biggest business challenge?
Barriers to clinical research. Its first placebo controlled Crohn’s study ended early after enrollment struggles tied to regulatory constraints on product handling. - How does Curio compete on price?
By formulating around cannabinoids, terpenes, and intended effects so customers buy an outcome, not a THC number, with unique formulations as the differentiator. - What is cGMP certification?
Current good manufacturing practice, a pharmaceutical grade manufacturing standard. Curio’s facility has held it since 2019 in anticipation of eventual federal regulation. - How does Curio decide which products survive?
It sets adoption and sales velocity targets at launch, monitors reorders and margin, then reprices, reformulates, or retires products that do not earn their place.
Source: IgniteIt: Cannabis Products Have to Earn Their Shelf Space. Curio Wellness Explains How.